Cargando…
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173367/ https://www.ncbi.nlm.nih.gov/pubmed/30323900 http://dx.doi.org/10.18632/oncotarget.26094 |
_version_ | 1783361112971935744 |
---|---|
author | Milevskiy, Michael J.G. Sandhu, Gurveen K. Wronski, Anna Korbie, Darren Brewster, Brooke L. Shewan, Annette Edwards, Stacey L. French, Juliet D. Brown, Melissa A. |
author_facet | Milevskiy, Michael J.G. Sandhu, Gurveen K. Wronski, Anna Korbie, Darren Brewster, Brooke L. Shewan, Annette Edwards, Stacey L. French, Juliet D. Brown, Melissa A. |
author_sort | Milevskiy, Michael J.G. |
collection | PubMed |
description | Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the protein-coding genes altered in BRCA1 deficient cells. However, the role of non-coding RNAs in BRCA1-deficient cells is poorly understood. To evaluate miRNA expression in BRCA1 deficient mammary cells, RNA sequencing was performed on the mammary glands of Brca1 knockout mice. We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development. We show that BRCA1 binds to putative cis-elements in promoter regions of the miRNAs with the potential to regulate their expression, and that four miRNAs (miR-29b-1-5p, miR-664, miR-16-2 and miR-744) significantly stratified the overall survival of basal-like tumours. Importantly the prognostic value of miR-29b-1-5p was higher in significance than several commonly used clinical biomarkers. These results emphasise the role of Brca1 in modulating expression of miRNAs and highlights the potential for BRCA1 regulated miRNAs to be informative biomarkers associated with BRCA1 loss and survival in breast cancer. |
format | Online Article Text |
id | pubmed-6173367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-61733672018-10-15 MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer Milevskiy, Michael J.G. Sandhu, Gurveen K. Wronski, Anna Korbie, Darren Brewster, Brooke L. Shewan, Annette Edwards, Stacey L. French, Juliet D. Brown, Melissa A. Oncotarget Research Paper Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the protein-coding genes altered in BRCA1 deficient cells. However, the role of non-coding RNAs in BRCA1-deficient cells is poorly understood. To evaluate miRNA expression in BRCA1 deficient mammary cells, RNA sequencing was performed on the mammary glands of Brca1 knockout mice. We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development. We show that BRCA1 binds to putative cis-elements in promoter regions of the miRNAs with the potential to regulate their expression, and that four miRNAs (miR-29b-1-5p, miR-664, miR-16-2 and miR-744) significantly stratified the overall survival of basal-like tumours. Importantly the prognostic value of miR-29b-1-5p was higher in significance than several commonly used clinical biomarkers. These results emphasise the role of Brca1 in modulating expression of miRNAs and highlights the potential for BRCA1 regulated miRNAs to be informative biomarkers associated with BRCA1 loss and survival in breast cancer. Impact Journals LLC 2018-09-11 /pmc/articles/PMC6173367/ /pubmed/30323900 http://dx.doi.org/10.18632/oncotarget.26094 Text en Copyright: © 2018 Milevskiy et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Milevskiy, Michael J.G. Sandhu, Gurveen K. Wronski, Anna Korbie, Darren Brewster, Brooke L. Shewan, Annette Edwards, Stacey L. French, Juliet D. Brown, Melissa A. MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title | MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title_full | MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title_fullStr | MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title_full_unstemmed | MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title_short | MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer |
title_sort | mir-29b-1-5p is altered in brca1 mutant tumours and is a biomarker in basal-like breast cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173367/ https://www.ncbi.nlm.nih.gov/pubmed/30323900 http://dx.doi.org/10.18632/oncotarget.26094 |
work_keys_str_mv | AT milevskiymichaeljg mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT sandhugurveenk mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT wronskianna mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT korbiedarren mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT brewsterbrookel mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT shewanannette mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT edwardsstaceyl mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT frenchjulietd mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer AT brownmelissaa mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer |